Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Diseases of the Esophagus

Predictive Role of Ctdna in Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy and Chemotherapy: A Prospective Cohort Study

View Full Paper
Ask AI
Bookmark
Share

Authors

JZJianfeng ZhouYYYu‐Shang YangYYYong Yuan

Discussion

Loading...

Member takes

Overview

Prospective cohort study evaluates ctDNA's predictive value for pathological responses in ESCC, highlighting its biomarkers.

Key Points

  • CtDNA dynamics correlate with pathological complete response rates and lymph node metastasis in ESCC.
  • Decreasing ctDNA levels during neoadjuvant therapy linked to improved pCR rates (p < 0.05).
  • The study analyzed 44 blood and 38 tissue samples from 23 patients, focusing on ctDNA changes.
  • CtDNA emergence signals higher metastatic risk, emphasizing its role as a predictive biomarker for ESCC.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/68c23cf6b210217d6478b8d5https://doi.org/10.1093/dote/doaf061.119
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1290. OPTIMIZING ESOPHAGEAL CANCER TREATMENT: PERSONALIZED CTDNA IMPROVES RESIDUAL DISEASE DETECTION AFTER NEOADJUVANT CHEMORADIOTHERAPY AND GUIDES ADAPTIVE ADJUVANT IMMUNOTHERAPY2025 · 1 citations
  2. 2ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma2025
  3. 3Gene‐specific ctDNA dynamics predict tumour burden and survival outcomes in ESCC: A prospective cohort study2025
  4. 4353. PROGNOSTIC VALUE OF CIRCULATING TUMOR DNA IN THE PERIOPERATIVE MANAGEMENT OF ESOPHAGEAL CANCER2025
  5. 5Circulating tumor DNA as a marker of molecular residual disease in resected esophageal squamous cell carcinoma2025 · 4 citations